

Communication

# Discovery of a covalent kinase inhibitor from a DNA-encoded small-molecule library X protein library selection

Alix I. Chan, Lynn M. McGregor, Tara Jain, and David R Liu

*J. Am. Chem. Soc.*, **Just Accepted Manuscript** • DOI: 10.1021/jacs.7b04880 • Publication Date (Web): 09 Jul 2017

Downloaded from <http://pubs.acs.org> on July 10, 2017

## Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications

# Discovery of a covalent kinase inhibitor from a DNA-encoded small-molecule library × protein library selection


Alix I. Chan, Lynn M. McGregor<sup>†</sup>, Tara Jain<sup>‡</sup>, and David R. Liu<sup>\*</sup>

The Broad Institute of Harvard and MIT, Howard Hughes Medical Institute, and the Department of Chemistry and Chemical Biology, Harvard University, 75 Ames St, Cambridge, Massachusetts 02142, USA.

## Supporting Information Placeholder

**ABSTRACT:** We previously reported interaction determination using unpurified proteins (IDUP), a method to selectively amplify DNA sequences encoding ligand:target pairs from a mixture of DNA-linked small molecules and unpurified protein targets in cell lysates. In this study we applied IDUP to libraries of DNA-encoded bioactive compounds and DNA-tagged human kinases to identify ligand:protein binding partners out of 32,096 possible combinations in a single solution-phase library × library experiment. The results recapitulated known small molecule:protein interactions and also revealed that ethacrynic acid is a novel ligand and inhibitor of MAP2K6 kinase. Ethacrynic acid inhibits MAP2K6 in part through alkylation of a non-conserved cysteine residue. This work validates the ability of IDUP to discover ligands for proteins of biomedical relevance.

Discovering small molecules that specifically modulate the activity of proteins of biomedical interest remains a crucial activity in the life sciences. DNA-encoded chemical libraries have emerged as a rich source of such small molecules as biological probes and leads for therapeutics development,<sup>1</sup> and are typically evaluated for binding to individual protein targets by affinity enrichment using immobilized, purified protein targets.<sup>2,3</sup> The effectiveness of these methods is limited by artefactual enrichment of library members that bind the solid support or non-physiologically relevant forms of target proteins, incomplete knowledge of the biological context necessary for the target to adopt its relevant form, and the inability to simultaneously explore interactions with multiple proteins of interest. Few methods of screening DNA-encoded libraries, such as selections on cell-surface displayed proteins,<sup>4</sup> parallel selections under varied conditions,<sup>3</sup> or the use of photocrosslinking probes to perform selections on unmodified proteins,<sup>5</sup> have begun to address these limitations.



**Figure 1.** Overview of IDUP. DNA-barcoded small molecules and proteins are combined in cell lysate. Primer extension, PCR and DNA sequencing reveal the identity of protein:ligand pairs.

To address some of these drawbacks, our group developed interaction determination using unpurified proteins (IDUP), a solution-phase method for *in vitro* identification of protein-binding ligands from combinations of ligands and unpurified proteins in a single experiment.<sup>6</sup> In IDUP, binding of a DNA-tagged protein and a DNA-encoded ligand stabilizes the hybridization of short (6- to 8-nt) complementary regions at the 3' ends of their associated DNA barcodes (Figure 1). The resulting short DNA duplex undergoes primer extension by a DNA polymerase, encoding both the small molecule and the protein it binds on a single oligonucleotide. Only these extended oligonucleotides with primer sequences from both libraries can undergo PCR amplification. Subsequent high-throughput DNA sequencing reveals the identities of all ligand:protein partner pairs. IDUP enables simultaneous evaluation of small molecule and protein libraries in a single experiment<sup>7</sup> in cell lysate<sup>6</sup> and leverages the efficiency of DNA-encoded libraries and high-throughput DNA sequencing. We previously validated IDUP's ability to enrich DNA sequences encoding known binding pairs from an excess of mock barcodes not conjugated to small molecules or target proteins.<sup>6</sup> In this study, we conducted a discovery-


oriented IDUP experiment using libraries of DNA-barcoded proteins and small molecules to identify novel binding pairs.

The majority of our library of protein targets consisted of human kinases, many of which are of biomedical interest. The ability of IDUP to assess the selectivity of small molecules could, in principle, distinguish promiscuous and selective kinase ligands. To assemble this protein library, we identified a set of 289 cytosolic and soluble human kinase ORFs included in pDONR221 vectors for Gateway cloning (Harvard PlasmID Repository). The ORFs were subcloned into an N-terminal SNAP-tag fusion protein plasmid by Gateway cloning to enable DNA barcoding. The resulting pDEST-SNAP-kinase vectors were transiently transfected into HEK293T cells. The corresponding cell lysates were individually treated with 31-nt benzylguanine-linked oligonucleotides (DNA-BG) that each contained a unique 6-nt barcode and the common 3' 8-nt hybridization region required for IDUP. DNA-BG barcodes were validated computationally and in a mock IDUP experiment to remove sequences that were subject to positive or negative PCR bias. Unlabeled SNAP protein was quenched using SNAP-Cell Block (New England Biolabs) and the lysates were pooled to obtain 236 SNAP-tagged, DNA-barcoded target proteins. In parallel, an aliquot of pooled lysates was quenched with SNAP-Cell Block, then combined with pooled DNA-BG, to generate a non-DNA-tagged negative control sample.

We constructed a library of DNA-linked compounds with annotated bioactivity, hypothesizing that those compounds may have more favorable solubility, stability, or protein-binding properties. We identified a candidate set of 500 carboxylic acid-containing compounds and 250 aliphatic primary amines within the databases of the Broad Institute and Harvard's Department of Chemistry and Chemical Biology. By inspection, we removed compounds containing functional groups that would interfere with DNA conjugation and compounds from overrepresented structural classes (e.g., quinolones, cephalosporins, or penicillins), arriving at a set of 177 carboxylate- and 87 amine-containing compounds.

Each small molecule's 43-nt DNA barcode included an internal 7-nt barcode and a constant 3' 8-nt hybridization region complementary to that of the protein library. Carboxylic acids were coupled to a 3'-amine-linked DNA oligonucleotide using DMT-MM or EDC and purified by HPLC, resulting in 97 DNA-linked compounds. Amine-containing small molecules were coupled to 3'-thiol-functionalized DNA using a heterobifunctional crosslinker containing both a maleimide and an NHS ester (Thermo Scientific Pierce), yielding an additional 39 DNA-linked compounds. We included the Bak peptide as a positive control, as we previously detected its binding to Bcl-xL protein ( $K_D = 480$  nM)<sup>8</sup> in the IDUP format.<sup>6</sup> The final library contained an equimolar mixture of each of the 136 DNA-linked compounds. The molecules span a range of chemical properties, including molecular weight (123 to 2,222 Da, mean = 357 Da), lipophilicity

(calculated cLogP of -9.8 to 7.4, mean = 1.8), and number of H-bond donors (1 to 40, mean = 4.7) (Figure S1).




**Figure 2.** Results of seven replicate IDUP experiments of combined protein and small molecule libraries. Eight DNA barcodes corresponding to bona fide interactions (Bak:Bcl-xL, PKI:PRKX, JQ1:BRD2, JQ1:BRD3, bisX:GSK3 $\alpha$ , EA:MAP2K6) enriched (red) out of 32,096 possibilities.  $K_D$  and  $IC_{50}$  values are for compounds and proteins not linked to DNA. Nonspecific amplification across some protein barcodes may arise from poor expression of those targets (see Fig. S2).

We combined 2 pmol of the DNA-linked small-molecule library with the DNA-tagged protein library and performed IDUP primer extension (see Supplemental Information p. S30). Extended products, encoding protein:ligand pairs, were selectively amplified by PCR and analyzed by high-throughput DNA sequencing. The abundance of each barcode out of the 32,096 possible ligand:protein combinations was compared to its frequency in the control IDUP experiment to define an enrichment value for each possible combination (Figure 2). Across seven technical replicates, the most significantly enriched sequence corresponded to Bcl-xL:Bak binding (205-fold average enrichment), the only interaction tested that we previously validated in an IDUP experiment.<sup>6</sup> In addition, we observed high enrichment (89.5-fold) of the barcodes corresponding to PKI peptide (a cAMP-dependent kinase inhibitor<sup>9</sup>) and PRKX (a cAMP-dependent kinase<sup>10</sup>). Two different barcodes corresponding to variants of the BET inhibitor JQ1 enriched for binding to BET family proteins BRD2 (6.8- or 6.9-fold,  $K_D = 128$  nM<sup>11</sup>) and BRD3 (15.2- or 19.4-fold,  $K_D = 60$  nM<sup>11</sup>). Although DNA-encoded library selections can suffer from interference between the DNA and binding of a library member to a protein, this possibility did not preclude enrichment of these ligand:protein partners. We did not observe a strong correlation between DNA-free bind-

ing affinity and IDUP enrichment, potentially due to factors such as the DNA tag affecting IDUP enrichment positively or negatively.

Next, we evaluated if protein:small-molecule combinations encoded by other enriched amplicons corresponded to bona fide protein:ligand pairs. We tested 11 interactions encoded by enriched barcodes in either kinase activity or binding assays using the corresponding non-DNA tagged ligands (Table S3). Using Z'-LYTE assays (Invitrogen) we measured the inhibition of PRKX by PKI ( $IC_{50} = 52$  nM) and GSK3 $\alpha$  by bisindolylmaleimide X (bisX)<sup>12</sup> (4.7-fold IDUP enrichment,  $IC_{50} = 115$  nM). Finally, we discovered that ethacrynic acid (EA) inhibits MAP2K6 (4.7-fold IDUP enrichment, Z'-LYTE  $IC_{50} = 4.5$   $\mu$ M).




**Figure 3.** Inhibition of MAP2K6 by EA is dependent on the Michael acceptor. The non-electrophilic analogs shown are >30-fold less potent.

EA is an FDA-approved loop diuretic that inhibits the NKCC symporter<sup>13</sup> and has not been previously reported to inhibit any kinases. EA contains a Michael acceptor that reacts with glutathione<sup>13</sup> and EA derivatives have been previously used as covalent bromodomain inhibitors.<sup>14</sup> We investigated whether it inhibits MAP2K6 by forming a covalent adduct with the protein. Non-electrophilic analogs of EA (dihydro-ethacrynic acid and tienilic acid) exhibited >30-fold weaker inhibition of MAP2K6 (Figure 3). Incubating MAP2K6 with EA yielded a +303 adduct in the intact protein mass spectrum, consistent with covalent modification by EA (Figure S3B). Sequential treatment of MAP2K6 with EA and then iodoacetamide (IAA), a cysteine alkylating agent, resulted in modification by IAA at only five of MAP2K6's six cysteines (Figure S3D), suggesting that EA modifies MAP2K6 at a cysteine residue. We analyzed EA-treated MAP2K6 by tryptic digest and MALDI-TOF and observed only one peptide (residues 37-49) with a modification consistent with EA adduct formation (Figure S4A). This peptide contains a single cysteine residue, and fragmentation of this peptide by tandem mass spectrometry confirmed that Cys38 was the site of covalent modification (Figure S4C).


To better assess the mechanism of EA inhibition, we incubated with EA a constitutively active MAP2K6 mutant containing phospho-mimetic S207E and T211E mutations (MAP2K6EE), dialyzed the protein into EA-free buffer, and observed 9-fold apparent loss of kinase activity in the Z'-LYTE assay. Preincubation of EA with a C38A point mutant of MAP2K6EE resulted in a smaller loss in inhibition potency of ~3.3-fold (Figure 4). Together, these results suggest

that covalent modification of MAP2K6 by EA at Cys38 is partially, but not solely, responsible for kinase inhibition.



**Figure 4.** Kinases were incubated with 100  $\mu$ M EA (+EA) or DMSO (-EA), then dialyzed to remove free EA. Activity was assayed as a function of kinase concentration. Ethacrynic acid inhibits MAP2K6 to a greater degree when Cys38 is present (left) than when this residue is mutated to an alanine (right).

A member of the MAP2K family, MAP2K6 activates p38 MAP kinase in response to environmental stresses.<sup>15</sup> Previous cheminformatic and proteome-wide studies implicated Cys128 (in the Gatekeeper region) or Cys196 (adjacent to the DFG motif) as more accessible or reactive towards small-molecule electrophiles.<sup>16</sup> In contrast, Cys38 is located within a non-active site region with poorly understood function<sup>17</sup> and is not conserved among other MAP2Ks (Figure S5). We confirmed that EA has higher affinity for MAP2K6 than other MAP2Ks (Figure 5). These trends are consistent with the results of the IDUP library  $\times$  library experiment, suggesting that IDUP can illuminate a compound's selectivity even within a protein family.



**Figure 5.** EA has higher affinity for MAP2K6 than the related MAP2K family members, as measured in both Lanthascreen Eu assays and our initial IDUP assay. n.d. = not determined.

The one-pot experiment described here enriched barcodes encoding seven different binding interactions out of 32,096 possible combinations. Only one (Bak:Bcl-xL) had been previously validated in the IDUP format, showing that IDUP is a generalizable method for detecting binding interactions in complex mixtures. The inhibition of MAP2K6 by EA by targeting Cys38 was also unexpected. Such selective probes could be used to investigate the role of MAP2K6 in redox sensing, development, and cancer.<sup>18</sup> EA's inhibition of MAP2K6, a cellular target unrelated to current uses of EA to treat edema or as a probe for GST function<sup>13</sup> or Wnt signaling<sup>19</sup>, suggests that further studies of EA and related compounds as biological probes might be fruitful. The discovery of this novel ligand interaction site in MAP2K6 through



IDUP highlights the potential of unbiased binding assays to reveal probes with unanticipated inhibition mechanisms.

To our knowledge, this work represents the first library × library DNA-encoded selection for the identification of previously unknown ligand:protein binding pairs. The approach described here, if applied to a genome-scale donor vector library,<sup>20</sup> could concurrently evaluate binding of DNA-encoded libraries of small molecules to many human proteins. DNA-encoded small-molecule libraries containing thousands to billions of chemically diverse members have been reported,<sup>1</sup> and only limited work has used DNA-encoded libraries to reveal cysteine-reactive covalent ligands<sup>21</sup> such as ethacrynic acid. Such a library of electrophiles could be used as covalent fragment leads against the proteome, analogous to current mass spectrometry-based activity based protein profiling methods.<sup>22</sup> Given the vast size of small molecule:protein interaction space that could be explored by integrating these existing resources, we anticipate that DNA-encoded library × library methods such as IDUP will find additional use in the rapid, unbiased discovery of small molecules capable of binding target proteins.

## ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website.

Supplemental figures and experimental methods (PDF).

## AUTHOR INFORMATION

### Corresponding Author

drliu@fas.harvard.edu

### Present Addresses

† Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States.

\* Harvard Medical School, Boston, MA 02115, United States.

### Funding Sources

This work was supported by NIH R01 EB022376 (formerly R01 GM065400), NIH R35 GM118062, DARPA N66001-14-2-4053, and the Howard Hughes Medical Institute.

### Notes

The authors declare the following competing financial interest: D.R.L. is a founder of Ensemble Therapeutics, a company that uses DNA-templated synthesis for drug discovery.

## ACKNOWLEDGMENT

JQ1-CO<sub>2</sub>H and JQ1-NH<sub>2</sub> were gifts from Jay Bradner. We thank Dr. Sunia Trauger for assistance with mass spectrometry.

## REFERENCES

- (1) (a) Zimmermann, G.; Neri, D. *Drug Discov. Today* **2016**, 1828-1834. (b) Goodnow, R. A., Jr.; Dumelin, C. E.; Keefe, A. D., *Nat. Rev. Drug Discov.* **2016**, 1-17. (c) Salamon, H.; Skopic, M. K.; Jung, K.; Bugain, O.; Brunschweiler, A. *ACS Chem. Biol.* **2016**, 296-307.

- (2) (a) Maiani, J. P.; McFedries, A.; Foda, Z. H.; Kleiner, R. E.; Du, X. Q.; Leissring, M. A.; Tang, W.-J.; Charron, M. J.; Seeliger, M. A.; Saghatelian, A.; Liu, D. R. *Nature* **2014**, 94-98. (b) Wichert, M.; Krall, N.; Decurtins, W.; Franzini, R. M.; Pretto, F.; Schneider, P.; Neri, D.; Scheuermann, J. *Nat. Chem.* **2015**, 241-9.
- (3) Soutter, H. H.; Centrella, P.; Clark, M. A.; Cuozzo, J. W.; Dumelin, C. E.; Guie, M. A.; Habeshian, S.; Keefe, A. D.; Kennedy, K. M.; Sigel, E. A.; Troast, D. M.; Zhang, Y.; Ferguson, A. D.; Davies, G.; Stead, E. R.; Breed, J.; Madhavapeddi, P.; Read, J. A. *Proc. Natl. Acad. Sci. USA* **2016**, E7880-E7889.
- (4) Wu, Z.; Graybill, T. L.; Zeng, X.; Platchek, M.; Zhang, J.; Bodmer, V. Q.; Wisnoski, D. D.; Deng, J.; Coppo, F. T.; Yao, G.; Tamburino, A.; Scavello, G.; Franklin, G. J.; Mataruse, S.; Bedard, K. L.; Ding, Y.; Chai, J.; Summerfield, J.; Centrella, P. A.; Messer, J. A.; Pope, A. J.; Israel, D. I. *ACS Comb. Sci.* **2015**, 722-31.
- (5) (a) Zhao, P.; Chen, Z.; Li, Y.; Sun, D.; Gao, Y.; Huang, Y.; Li, X. *Agnew. Chem. Int. Ed.* **2014**, 53, 10056-10059. (b) Li, Gang.; Zheng, W.; Chen, Z.; Zhou, Y.; Liu, Y.; Yang J.; Huang, Y.; Li, X. *Chem. Sci.* **2015**, 7098-7104.
- (6) McGregor, L. M.; Jain, T.; Liu, D. R. *J. Am. Chem. Soc.* **2014**, 3264-70.
- (7) Wu, C. Y.; Wang, D. H.; Wang, X. B.; Dixon, S. M.; Meng, L. P.; Ahadi, S.; Enter, D. H.; Chen, C. Y.; Kato, J.; Leon, L. J.; Ramirez, L. M.; Maeda, Y.; Reis, C. F.; Ribeiro, B.; Weems, B.; Kung, H. J.; Lam, K. S. *ACS Comb. Sci.* **2016**, 320-329.
- (8) Petros, A. M.; Nettesheim, D. G.; Wang, Y.; Olejniczak, E. T.; Meadows, R. P.; Mack, J.; Swift, K.; Matayoshi, E. D.; Zhang, H.; Thompson, C. B.; Fesik, S. W. *Protein Sci.* **2000**, 2528-2534.
- (9) Glass, D. B.; Lundquist, L. J.; Katz, B. M.; Walsh, D. A., *J. Biol. Chem.* **1989**, 14579-84.
- (10) Li, X.; Li, H. P.; Amsler, K.; Hyink, D.; Wilson, P. D.; Burrow, C. R., *Proc. Natl. Acad. Sci. USA* **2002**, 9260-5.
- (11) Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E., *Nature* **2010**, 1067-73.
- (12) Brehmer, D.; Godl, K.; Zech, B.; Wissing, J.; Daub, H., *Mol. Cell Proteomics* **2004**, 490-500.
- (13) (a) Molnar, J.; Somberg, J. C., *Am J Ther* **2009**, 16, 86-92. (b) Maron, B. A.; Rocco, T. P., *Goodman & Gilman's: The Pharmacological Basis of Therapeutics*, 12e, Brunton, L. L.; Chabner, B. A.; Knollmann, B. C., Eds. McGraw-Hill Education: New York, NY, 2011.
- (14) Daguer, J.-P.; Zambaldo, C.; Abegg, D.; Barluenga, S.; Tallant, C.; Müller, S.; Adibekian, A.; Winssinger, N. *Agnew. Chem. Int. Ed.* **2015**, 6057-6061.
- (15) Raman, M.; Chen, W.; Cobb, M. H. *Oncogene* **2007**, 3100-12.
- (16) (a) Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhrlage, S. J.; Jones, L. H.; Gray, N. S. *Chem. Biol.* **2013**, 146-59. (b) Weerapana, E.; Wang, C.; Simon, G. M.; Richter, F.; Khare, S.; Dillon, M. B.; Bachovich, D. A.; Mowen, K.; Baker, D.; Cravatt, B. F. *Nature* **2010**, 790-5.
- (17) Matsumoto, T.; Kinoshita, T.; Matsuzaka, H.; Nakai, R.; Kirii, Y.; Yokota, K.; Tada, T., *J. Biochem.* **2012**, 541-549.
- (18) (a) Diao, Y.; Liu, W.; Wong, C. C.; Wang, X.; Lee, K.; Cheung, P. Y.; Pan, L.; Xu, T.; Han, J.; Yates, J. R., 3rd; Zhang, M.; Wu, Z. *Proc. Natl. Acad. Sci. USA* **2010**, 20974-9. (b) Warr, N.; Siggers, P.; Carre, G. A.; Wells, S.; Greenfield, A. *Biol. Reprod.* **2016**, 103. (c) Mitra, A. P.; Almal, A. A.; George, B.; Fry, D. W.; Lenehan, P. F.; Pagliarulo, V.; Cote, R. J.; Datar, R. H.; Worzel, W. P. *BMC Cancer* **2006**, 6. (d) Parry, A. A.; Baba, R. A.; Bhat, H. F.; Wani, L.; Mokhdomi, T. A.; Mushtaq, U.; Bhat, S. S.; Kirmani, D.; Kuchay, S.; Wani, M. M.; Khanday, F. A., *Cancer Invest.* **2014**, 416-422.
- (19) Lu, D.; Liu, J. X.; Endo, T.; Zhou, H.; Yao, S.; Willert, K.; Schmidt-Wolf, I. G.; Kipps, T. J.; Carson, D. A. *PLoS One* **2009**, e8294.
- (20) Yang, X.; Boehm, J. S.; Yang, X.; Salehi-Ashtiani, K.; Hao, T.; Shen, Y.; Lubonja, R.; Thomas, S. R.; Alkan, O.; Bhimdi, T.; Green, T. M.; Johannessen, C. M.; Silver, S. J.; Nguyen, C.; Murray, R. R.; Hieronymus, H.; Balcha, D.; Fan, C.; Lin, C.; Ghamsari, L.; Vidal, M.; Hahn, W. C.; Hill, D. E.; Root, D. E. *Nat. Methods* **2011**, 659-61.
- (21) Zambaldo, C.; Daguer, J. P.; Saabach, J.; Barluenga, S.; Winssinger, N. *Medchemcomm* **2016**, 1340-1351.
- (22) Backus, K. M.; Correia, B. E.; Lum, K. M.; Forli, S.; Horning, B. D.; González-Páez, G. E.; Chatterjee, S.; Lanning, B. R.; Teijaro, J. R.; Olsen, A. J.; Wolan, D. W.; Cravatt, B. F. *Nature* **2016**, 570-574.

